Emyria Limited (ASX:EMD ) is an Australian public company that commenced trading on the Australian Securities Exchange (ASX) on 12 February 2020, a data-backed, drug development company that elevates clinical care and delivers deeper clinical insights.
We see a global opportunity and believe that much of what we want to achieve today is already possible by bringing together the right talent and technology and staying caring, curious and courageous.
Reports & Updates
Investor Communication Update
Following the passing of the Corporations Amendments (meetings and Documents) Act 2022 in February 2022, the way we communicate regarding Notices of Meeting and Annual Reports has changed.
More information, including contact details for updates to our shares and options register, is available at the button below.
The future of healthcare is personalised medicine enabled by digital technology but configured in a way so we can learn as we go.
Code of Conduct
Risk Committee Charter
Statement of Values